US 10760076
Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion
granted A61KA61K31/7105A61K9/0019
Quick answer
US patent 10760076 (Use of single-stranded antisense oligonucleotide in prevention or treatment of genetic diseases involving a trinucleotide repeat expansion) held by ProQR Therapeutics II B.V. expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ProQR Therapeutics II B.V.
- Grant date
- Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/7105, A61K9/0019, A61K9/0048, A61P